Solid Tumors account for 30% of all childhood cancers. Sarcoma, a cancer that develops in the bone and soft tissue are the most common types of non-central nervous systems solid tumors diagnosed in children.
While advances have been made in survival rates over the past several decades, these solid tumors remain among the most resistant to standard therapy when the cancer relapses or does not respond to initial treatment.
Seattle Children’s has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer fighting CAR T-cells will target the EGFR protein expressed in many childhood sarcoma, kidney, and neuroblastoma tumors.
By arming the CAR T-cells with and antibody known as EGFR806, researchers led by Dr. Mike Jensen hope to selectively find and destroy solid tumor cells expressing EGFR with limited toxicity to normal tissues. The study plans to enroll approximately 36 patients.
Make Some Noise: Cure Kids Cancer Foundation and its northwest chapter continue to support this promising childhood cancer research work at Seattle Children’s.
